Question explored with the scientific record
Why did they lower target levels for blood pressure and sugar
The short version: the targets were lowered because trials showed fewer heart attacks and strokes at lower numbers, but the same trials showed real harms, and the trade-off is not as clean as the guidelines suggest.
The push to lower blood pressure targets came from trials like SPRINT, which found that pushing systolic pressure below 120 (instead of below 140) cut major cardiovascular events by about a third in high-risk older adults [1]. A 2016 meta-analysis of 19 trials with nearly 45,000 people found intensive lowering cut major events by 14%, strokes by 22%, and heart attacks by 13% [13]. That looks like a win.
But the same trials logged the costs. In SPRINT, intensive treatment raised the risk of a serious hypotension event by 67% [5][12]. A 2018 bivariate analysis of four trials found intensive treatment did not achieve net clinical benefit once serious adverse events were counted [2]. In the ACCORD diabetes trial, intensive blood pressure control cut strokes but required more drugs and raised kidney injury, hypotension, and other adverse events [3]. A Cochrane review found lower targets in diabetics gave no mortality benefit and increased serious adverse events [11].
The sugar story is murkier. Intensive glucose control cut microvascular complications in the DCCT and UKPDS trials [6][9]. But ACCORD, ADVANCE, and VADT all failed to show cardiovascular benefit from intensive control, and ACCORD was stopped early because intensive treatment increased deaths [7][9]. Intensive control roughly tripled severe hypoglycemia risk in DCCT [10].
| Trial | What intensive control did | The cost |
|---|---|---|
| SPRINT (BP) | 34% fewer cardiovascular events [1] | 67% more serious hypotension [5] |
| ACCORD (BP) | Fewer strokes [3] | More kidney injury, hypotension [3] |
| ACCORD (glucose) | No CV benefit [7] | More deaths, trial stopped early [7] |
| DCCT (glucose) | Fewer microvascular complications [6] | 3x severe hypoglycemia [10] |
The guidelines lowered targets because the cardiovascular benefits were real in trials. But the harms were real too, and the trials that showed net benefit enrolled high-risk patients, not healthy people. The evidence does not support one target for everyone. It supports individualizing based on age, frailty, and risk [4][8].
My call: lower targets help high-risk patients but the harms are underweighted in the guidelines, and the evidence does not justify aggressive targets for everyone. Confidence: moderate.
Sources used 13
-
Blood pressure targets for elderly patients: new SPRINT data
The study analyzes outcomes from the SPRINT trial, revealing that intensive blood pressure control in elderly patients (aged ≥75 years) significantly reduces cardiovascular events and mortality compared to standard treatment, despite some unexpected findings regarding myocardial…
DOI: 10.1038/nrneph.2016.96 -
Effect of intensive versus standard blood pressure control on major adverse cardiac events and serious adverse events: A bivariate analysis of randomized controlled trials
This study conducts a bivariate analysis of randomized controlled trials comparing intensive versus standard blood pressure control, revealing that intensive strategies do not achieve a net clinical benefit when balancing the reduction of major adverse cardiac events against the…
DOI: 10.1080/10641963.2018.1462373 -
Hypertension in patients with diabetes: questions
A commentary synthesizing ACCORD BP trial findings with prior diabetes/BP research to discuss optimal blood pressure targets in diabetes, highlighting that aggressive BP lowering can reduce stroke but increase adverse effects and must be balanced with glycemic control and indivi…
DOI: 10.1111/j.1753-0407.2010.00083.x -
Changes in frailty, intensive blood pressure treatment, and risks of adverse clinical outcomes: a post hoc analysis of the SPRINT trial
Post hoc analysis of the SPRINT trial evaluating how 12-month changes in frailty status relate to cardiovascular disease, all-cause mortality, and serious adverse events, and whether frailty dynamics modify the benefits of intensive blood pressure control in older adults at high…
DOI: 10.1186/s12916-025-04382-7 -
Syncope, Hypotension, and Falls in the Treatment of Hypertension: Results from the Randomized Clinical Systolic Blood Pressure Intervention Trial
Intensive SBP lowering to less than 120 mmHg increases risk of hypotension and possibly syncope, but does not increase falls, with no age-by-treatment interaction; older adults have higher absolute risk.
DOI: 10.1111/jgs.15236 -
Glycemic Control and Complications in Type 2 Diabetes Mellitus
This article reviews how glycemic control influences microvascular and macrovascular complications in type 2 diabetes, highlighting that complications can occur even at HbA1c below target, discussing mechanisms of glucotoxicity/glucolipotoxicity, and evaluating major trials to c…
DOI: 10.1016/j.amjmed.2009.12.004 -
Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials
This position statement reviews the implications of the ACCORD, ADVANCE, and VA Diabetes Trials on intensive glycemic control and its effects on cardiovascular events in diabetes patients, highlighting the lack of significant cardiovascular benefits despite established microvasc…
DOI: 10.1016/j.jacc.2008.10.008 -
Antidiabetic Therapy in End‐Stage Renal Disease
A comprehensive review of antidiabetic therapy in patients with diabetes and end-stage renal disease (ESRD), detailing altered glucose homeostasis, challenges in glycemic assessment, and practical considerations across noninsulin therapies, insulin regimens, dialysis modalities,…
DOI: 10.1111/sdi.12368 -
The effect of intensive glycaemic control on cardiovascular outcomes
This 2010 review synthesizes major randomized trials of intensive glycemic control in both type 1 and type 2 diabetes, showing that early, gradual tightening of glucose reduces microvascular complications and can yield a long-term ('legacy') reduction in macrovascular events in …
DOI: 10.1111/j.1463-1326.2010.01199.x -
Hypoglycemia in the Diabetes Control and Complications Trial
A multicenter randomized trial (the DCCT) comparing intensive versus conventional diabetes therapy found that intensive treatment markedly increases the risk of severe hypoglycemia, with risk strongly driven by current HbA1c levels and prior hypoglycemia history, while varying b…
DOI: 10.2337/diab.46.2.271 -
Blood pressure targets for hypertension in people with diabetes mellitus
This review evaluates the impact of lower blood pressure targets (<130/85 mmHg) compared to standard targets (<140-160/90-100 mmHg) on mortality and morbidity in individuals with diabetes, finding no significant benefits and an increase in serious adverse events associated with …
DOI: 10.1002/14651858.cd008277.pub2 -
Intensive antihypertensive treatment and serious adverse events in older people
An analysis of serious adverse events from the SPRINT trial found that intensive blood pressure lowering (SBP <120 mm Hg) increased the risk of hypotension-related events regardless of age, with no significant differences in syncope or falls.
DOI: 10.1136/dtb.2018.12.000046 -
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
This systematic review and meta-analysis assess the efficacy and safety of intensive blood pressure-lowering strategies in high-risk patients, revealing significant reductions in major cardiovascular events without clear adverse effects on total mortality or end-stage kidney dis…
DOI: 10.1016/S0140-6736(15)00805-3